Rare subtypes of adenocarcinoma of the lung

by Ou, S.-H.I., Kawaguchi, T., Soo, R.A., Kitaichi, M.
Published 2014

ROS1 as a 'druggable' receptor tyrosine kinase: Lessons learned from inhibiting the ALK pathway

by Ou, S.-H.I., Tan, J., Yen, Y., Soo, R.A.
Published 2014

Targeting ROS1 with anaplastic lymphoma kinase inhibitors: A promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer

by Chin, L.P., Soo, R.A., Soong, R., Ou, S.-H.I.
Published 2014

Will the requirement by the US FDA to simultaneously co-develop companion diagnostics (CDx) delay the approval of receptor tyrosine kinase inhibitors for RTK-rearranged (ROS1-, RET...

by Ou, S.-H.I, Soo, R.A, Kubo, A, Kawaguchi, T, Ahn, M.-J
Published 2020

Differences in outcome and toxicity between Asian and caucasian patients with lung cancer treated with systemic therapy

by Soo, R.A., Kawaguchi, T., Loh, M., Ou, S.-H.I., Shieh, M.P., Cho, B.-C., Mok, T.S., Soong, R.
Published 2014

Ethnic differences in survival outcome in patients with advanced stage non-small cell lung cancer: Results of a meta-analysis of randomized controlled trials

by Soo, R.A., Loh, M., Mok, T.S., Ou, S.-H.I., Cho, B.-C., Yeo, W.-L., Tenen, D.G., Soong, R.
Published 2014